These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 16449807)

  • 21. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.
    Albers GW; Diener HC; Frison L; Grind M; Nevinson M; Partridge S; Halperin JL; Horrow J; Olsson SB; Petersen P; Vahanian A;
    JAMA; 2005 Feb; 293(6):690-8. PubMed ID: 15701910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New possibilities in anticoagulant management of atrial fibrillation.
    Waldo AL
    Rev Cardiovasc Med; 2004; 5 Suppl 5():S30-8. PubMed ID: 15619613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis.
    Berry C; Norrie J; McMurray JJ
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):149-51. PubMed ID: 16025234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New perspectives for anticoagulation in non-rheumatic atrial fibrillation: oral antithrombins].
    Scardi S; Giansante C
    Ital Heart J Suppl; 2004 Sep; 5(9):705-11. PubMed ID: 15568608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of hypertension on anticoagulated patients with atrial fibrillation.
    Lip GY; Frison L; Grind M;
    Eur Heart J; 2007 Mar; 28(6):752-9. PubMed ID: 17289744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ximelagatran in prevention of cardiovascular events.
    Molckovsky D; Boucher M
    Issues Emerg Health Technol; 2004 Nov; (62):1-4. PubMed ID: 15565751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
    Francis CW; Berkowitz SD; Comp PC; Lieberman JR; Ginsberg JS; Paiement G; Peters GR; Roth AW; McElhattan J; Colwell CW;
    N Engl J Med; 2003 Oct; 349(18):1703-12. PubMed ID: 14585938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
    Tangelder MJ; Frison L; Weaver D; Wilcox RG; Bylock A; Emanuelsson H; Held P; Oldgren J
    Am Heart J; 2008 Feb; 155(2):382-7. PubMed ID: 18215612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
    Fox KA; Piccini JP; Wojdyla D; Becker RC; Halperin JL; Nessel CC; Paolini JF; Hankey GJ; Mahaffey KW; Patel MR; Singer DE; Califf RM
    Eur Heart J; 2011 Oct; 32(19):2387-94. PubMed ID: 21873708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ximelagatran: a new oral anticoagulant.
    Hrebickova L; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(6):397-408. PubMed ID: 14633322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.
    Agarwal S; Hachamovitch R; Menon V
    Arch Intern Med; 2012 Apr; 172(8):623-31; discussion 631-3. PubMed ID: 22450212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of ximelagatran and warfarin on stroke subtypes in atrial fibrillation.
    Teitelbaum JS; von Kummer R; Gjesdal K; Kristinsson A; Gahn G; Albers GW;
    Can J Neurol Sci; 2008 May; 35(2):160-5. PubMed ID: 18574928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation.
    Lip GY; Frison L; Grind M;
    J Intern Med; 2008 Jul; 264(1):50-61. PubMed ID: 18266660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data.
    Gjesdal K; Feyzi J; Olsson SB
    Heart; 2008 Feb; 94(2):191-6. PubMed ID: 17483128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ximelagatran.
    Choudhury A; Goyal D; Lip GY
    Drugs Today (Barc); 2006 Jan; 42(1):3-19. PubMed ID: 16511607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Olsson SB; Rasmussen LH; Tveit A; Jensen E; Wessman P; Panfilov S; Wåhlander K
    Thromb Haemost; 2010 Mar; 103(3):604-12. PubMed ID: 20076850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.
    White HD; Gruber M; Feyzi J; Kaatz S; Tse HF; Husted S; Albers GW
    Arch Intern Med; 2007 Feb; 167(3):239-45. PubMed ID: 17296878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis.
    Lip GY; Edwards SJ
    Thromb Res; 2006; 118(3):321-33. PubMed ID: 16198396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials.
    Cleland JG; Shelton R; Nikitin N; Ford S; Frison L; Grind M
    Eur J Heart Fail; 2007; 9(6-7):730-9. PubMed ID: 17360232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New approaches to anticoagulation in atrial fibrillation.
    Petersen P
    Curr Cardiol Rep; 2004 Sep; 6(5):354-64. PubMed ID: 15306092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.